Eintrag weiter verarbeiten
Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
Gespeichert in:
| Zeitschriftentitel: | Clinical Medicine Insights: Cardiology |
|---|---|
| Personen und Körperschaften: | , |
| In: | Clinical Medicine Insights: Cardiology, 7, 2013, S. CMC.S11516 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
SAGE Publications
|
| Schlagwörter: |
| author_facet |
Whitbeck, Matthew G. Applegate, Robert J. Whitbeck, Matthew G. Applegate, Robert J. |
|---|---|
| author |
Whitbeck, Matthew G. Applegate, Robert J. |
| spellingShingle |
Whitbeck, Matthew G. Applegate, Robert J. Clinical Medicine Insights: Cardiology Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform Cardiology and Cardiovascular Medicine |
| author_sort |
whitbeck, matthew g. |
| spelling |
Whitbeck, Matthew G. Applegate, Robert J. 1179-5468 1179-5468 SAGE Publications Cardiology and Cardiovascular Medicine http://dx.doi.org/10.4137/cmc.s11516 <jats:p> Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing. The cobalt chromium EES fluoropolymer XIENCE V stent has been the most extensively studied of such stents. In animal models, this stent demonstrated minimal vessel inflammation, a biologically active endothelium with strut coverage similar to a bare metal stent, and inhibition of intimal hyperplasia comparable to that seen with sirolimus-eluting stents. The SPIRIT family of clinical trials demonstrated low rates of late loss, and clinical restenosis, as well as low rates of very late stent thrombosis. These excellent clinical outcomes addressed limitations of the 1st generation DES, and substantiated widespread clinical use of the EES platform. </jats:p> Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform Clinical Medicine Insights: Cardiology |
| doi_str_mv |
10.4137/cmc.s11516 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuNDEzNy9jbWMuczExNTE2 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuNDEzNy9jbWMuczExNTE2 |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
SAGE Publications, 2013 |
| imprint_str_mv |
SAGE Publications, 2013 |
| issn |
1179-5468 |
| issn_str_mv |
1179-5468 |
| language |
English |
| mega_collection |
SAGE Publications (CrossRef) |
| match_str |
whitbeck2013secondgenerationdrugelutingstentsareviewoftheeverolimuselutingplatform |
| publishDateSort |
2013 |
| publisher |
SAGE Publications |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Medicine Insights: Cardiology |
| source_id |
49 |
| title |
Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| title_unstemmed |
Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| title_full |
Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| title_fullStr |
Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| title_full_unstemmed |
Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| title_short |
Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| title_sort |
second generation drug-eluting stents: a review of the everolimus-eluting platform |
| topic |
Cardiology and Cardiovascular Medicine |
| url |
http://dx.doi.org/10.4137/cmc.s11516 |
| publishDate |
2013 |
| physical |
CMC.S11516 |
| description |
<jats:p> Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing. The cobalt chromium EES fluoropolymer XIENCE V stent has been the most extensively studied of such stents. In animal models, this stent demonstrated minimal vessel inflammation, a biologically active endothelium with strut coverage similar to a bare metal stent, and inhibition of intimal hyperplasia comparable to that seen with sirolimus-eluting stents. The SPIRIT family of clinical trials demonstrated low rates of late loss, and clinical restenosis, as well as low rates of very late stent thrombosis. These excellent clinical outcomes addressed limitations of the 1st generation DES, and substantiated widespread clinical use of the EES platform. </jats:p> |
| container_start_page |
0 |
| container_title |
Clinical Medicine Insights: Cardiology |
| container_volume |
7 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792331096896045059 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T13:34:28.954Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Second+Generation+Drug-Eluting+Stents%3A+A+Review+of+the+Everolimus-Eluting+Platform&rft.date=2013-01-01&genre=article&issn=1179-5468&volume=7&pages=CMC.S11516&jtitle=Clinical+Medicine+Insights%3A+Cardiology&atitle=Second+Generation+Drug-Eluting+Stents%3A+A+Review+of+the+Everolimus-Eluting+Platform&aulast=Applegate&aufirst=Robert+J.&rft_id=info%3Adoi%2F10.4137%2Fcmc.s11516&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792331096896045059 |
| author | Whitbeck, Matthew G., Applegate, Robert J. |
| author_facet | Whitbeck, Matthew G., Applegate, Robert J., Whitbeck, Matthew G., Applegate, Robert J. |
| author_sort | whitbeck, matthew g. |
| container_start_page | 0 |
| container_title | Clinical Medicine Insights: Cardiology |
| container_volume | 7 |
| description | <jats:p> Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing. The cobalt chromium EES fluoropolymer XIENCE V stent has been the most extensively studied of such stents. In animal models, this stent demonstrated minimal vessel inflammation, a biologically active endothelium with strut coverage similar to a bare metal stent, and inhibition of intimal hyperplasia comparable to that seen with sirolimus-eluting stents. The SPIRIT family of clinical trials demonstrated low rates of late loss, and clinical restenosis, as well as low rates of very late stent thrombosis. These excellent clinical outcomes addressed limitations of the 1st generation DES, and substantiated widespread clinical use of the EES platform. </jats:p> |
| doi_str_mv | 10.4137/cmc.s11516 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuNDEzNy9jbWMuczExNTE2 |
| imprint | SAGE Publications, 2013 |
| imprint_str_mv | SAGE Publications, 2013 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1179-5468 |
| issn_str_mv | 1179-5468 |
| language | English |
| last_indexed | 2024-03-01T13:34:28.954Z |
| match_str | whitbeck2013secondgenerationdrugelutingstentsareviewoftheeverolimuselutingplatform |
| mega_collection | SAGE Publications (CrossRef) |
| physical | CMC.S11516 |
| publishDate | 2013 |
| publishDateSort | 2013 |
| publisher | SAGE Publications |
| record_format | ai |
| recordtype | ai |
| series | Clinical Medicine Insights: Cardiology |
| source_id | 49 |
| spelling | Whitbeck, Matthew G. Applegate, Robert J. 1179-5468 1179-5468 SAGE Publications Cardiology and Cardiovascular Medicine http://dx.doi.org/10.4137/cmc.s11516 <jats:p> Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing. The cobalt chromium EES fluoropolymer XIENCE V stent has been the most extensively studied of such stents. In animal models, this stent demonstrated minimal vessel inflammation, a biologically active endothelium with strut coverage similar to a bare metal stent, and inhibition of intimal hyperplasia comparable to that seen with sirolimus-eluting stents. The SPIRIT family of clinical trials demonstrated low rates of late loss, and clinical restenosis, as well as low rates of very late stent thrombosis. These excellent clinical outcomes addressed limitations of the 1st generation DES, and substantiated widespread clinical use of the EES platform. </jats:p> Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform Clinical Medicine Insights: Cardiology |
| spellingShingle | Whitbeck, Matthew G., Applegate, Robert J., Clinical Medicine Insights: Cardiology, Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform, Cardiology and Cardiovascular Medicine |
| title | Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| title_full | Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| title_fullStr | Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| title_full_unstemmed | Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| title_short | Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| title_sort | second generation drug-eluting stents: a review of the everolimus-eluting platform |
| title_unstemmed | Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform |
| topic | Cardiology and Cardiovascular Medicine |
| url | http://dx.doi.org/10.4137/cmc.s11516 |